NEW YORK, February 2, 2017 /PRNewswire/ --
On Wednesday, February 01, 2017, US markets were mixed as 3 sectors closed in green, 4 sectors finished in red, and 2 sectors ended flat for the day. Major US indices were bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,642.65, up 0.50%; the Dow Jones Industrial Average edged 0.14% higher, finishing at 19,890.94; and the S&P 500 closed at 2,279.55, marginally up 0.03%. This Thursday morning, Stock-Callers.com looks at the performance of these four Medical Laboratories & Research stocks: Organovo Holdings Inc. (NASDAQ: ONVO), DexCom Inc. (NASDAQ: DXCM), Quest Diagnostics Inc. (NYSE: DGX), and Alere Inc. (NYSE: ALR). You can access our complimentary research reports on these stocks now at:
San Diego, California headquartered Organovo Holdings Inc.'s stock edged 0.27% higher, to close the day at $3.70. The stock recorded a trading volume of 957,601 shares. Organovo Holdings' shares have surged 9.14% in the last one month, 48.59% in the previous three months, and 92.71% in the past one year. The Company's shares are trading 6.13% and 6.49% above its 50-day and 200-day moving averages, respectively. Additionally, Shares of the Company, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 56.57.
On January 25th, 2017, research firm Raymond James initiated an 'Outperform' rating on the Company's stock. Visit us today and download your complete report on ONVO for free at:
On Wednesday, shares in San Diego, California headquartered DexCom Inc. ended the session 0.37% higher at $79.44 with a total volume of 936,156 shares traded. DexCom's shares have gained 33.07% in the last one month and 1.53% in the previous three months. Furthermore, the stock has gained 10.29% in the past one year. The stock is trading 15.09% above its 50-day moving average and 4.25% above its 200-day moving average. Moreover, shares of the Company, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 64.29.
On January 03rd, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight', with a target price of $66 per share. The complimentary research report on DXCM can be accessed at:
On Wednesday, shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 1.27 million shares, which was higher than their three months average volume of 1.13 million shares. The stock ended the day 0.69% higher at $92.55. Shares of the Company, which provides diagnostic testing information and services in the US and internationally, are trading at a PE ratio of 19.64. Quest Diagnostics' stock has advanced 1.20% in the last one month and 14.20% in the previous three months. Furthermore, the stock has surged 47.62% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 2.23% and 11.61%, respectively. Furthermore, Quest Diagnostics' shares have an RSI of 56.65.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $108 per share. Register for free on Stock-Callers.com and download the PDF research report on DGX at:
Waltham, Massachusetts headquartered Alere Inc.'s stock finished Wednesday's session 0.95% higher at $37.35 with a total volume of 568,083 shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 4.65% and 8.51%, respectively. Shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 33.43. Get free access to your research report on ALR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA